[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-661584-105":59,"doc-detail-661584-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","medicine-prices-and-availability-whohai-project","Medicine Prices and Availability - WHO/HAI Project","","Outcome of the WHO/public interest NGOs roundtable focuses on the WHO/HAI project to improve availability and affordability of essential medicines. It outlines a reliable methodology for collecting and analysing medicine price and availability data across healthcare sectors and regions, supporting price transparency, guidance on pricing policy options, and monitoring their impact. It includes facility-based measures covering medicine prices, availability, treatment affordability, and supply-chain components, with an updated second edition and tools for international comparisons.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/medicine-prices-and-availability-whohai-project/661584/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/medicine-prices-and-availability-whohai-project/661584.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-10-28",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the WHO/HAI project aim to improve regarding essential medicines?","Question",{"text":112,"@type":113},"It aims to improve the availability and affordability of essential medicines through better measurement and policy support.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methodology does the project develop for collecting data?",{"text":117,"@type":113},"It develops and applies a reliable methodology to collect and analyse medicine price and availability data across healthcare sectors and regions within a country.",{"name":119,"@type":110,"acceptedAnswer":120},"Which measures are included in the facility-based surveys?",{"text":121,"@type":113},"Facility-based surveys measure medicine prices, medicine availability, affordability of treatments, and components in the supply chain.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},661584,1793170739,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":144},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Medicine prices, availabilty, affordability and price components  \nMargaret Ewen,  \nCoordinator, Global Projects (Pricing) Health Action International  \nWHO, WIPO and WTO Joint Technical Symposium  \n16 July 2010  \nOutcome of the WHO/public interest NGOs Roundtable on Pharmaceuticals:  \nWHO/HAI Project on  \nMedicine Prices and Availability  \nimprove the availability and affordability essential medicines  \n• Develop and apply a reliable methodology for collecting and analysing price and availability data across healthcare sectors and regions in a country  \n• Price transparency; survey data on a freely accessible website allowing international comparisons  \n• Provide guidance on pricing policy options and monitoring their impact  \nFacility-based survey that measures:  \n• medicine prices  \n• medicine availability  \n• affordability of treatments  \n• components in the supply chain Launched at World Health Assembly in 2003 2 nd edition published in 2008 includes:  \n• adjustments to methodology  \n• practical advice based on prior surveys  \n• additional tools and resources  \n• new guidance on international comparisons, policy options, advocacy and regular monitoring  \nWHO/HAI standard methodology for measuring medicine prices and availability  \nManual, tools, database and more:  \n[www.haiweb.org/medicineprices](www.haiweb.org/medicineprices)  \nMedicine price and availability surveys to date  \nusing WHO/HAI methodology  \nMedian % availability by World Bank income group  \nA Cameron, M Ewen, D Ross Degnan, D Ball, R Laing The Lancet online 1 Dec2008  \nmax min  \n􀂃 mean  \npublic sector generics  \nprivate sector generics  \nprivate sector originator brands  \nMean % availability of medicines to treat acute and chronic diseases  \nI Roubos, A Cameron , M Ewen, Laing R et al 2009  \n\n|  |  | Acute conditions | Chronic conditions | Difference: acute-chronic |\n| --- | --- | --- | --- | --- |\n| Public\u003Cbr>sector | Generics (n=35) | 53.5% | 36% | 17.5% |\n|  | Originator brands (n=34) | 5.5% | 9.6% | -4.1% |\n|  | Any product type (n=35) | 55.9% | 41.6% | 14.3% |\n| Private\u003Cbr>sector | Generics (n=40) | 66.2% | 54.7% | 11.5% |\n|  | Originator brands (n=39) | 39.1% | 39.1% | 0% |\n|  | Any product type (n=40) | 74.8% | 69.2% | 5.6% |\n\nMedian government procurement prices, lowest priced generics  \nmax min  \n􀂃 mean  \nPublic sector patient prices  \n• In many countries medicines are free but availability is often very poor  \n• Good procurement prices are not always passed on to patients e.g. Khartoum over 500% mark-up  \n• In some countries, public sector prices are similar to private sector prices e.g. China, Shanghai  \nMedian patient prices, private sector  \nAdjusted CPI & PPP  \nMed MPR  \n90  \n80  \n70  \n60  \n50  \n40  \n30  \n20  \n10  \n0  \n\n|  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- |\n|  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |\n|  |  | |  41.6 | 40.1 |  |  |\n|  |  | 39.7 |  |  |  |  |\n|  |  |  |  |  |  |  |\n| |  12.5 |  |  |  |  14 |  17.5 |\n| |  |  |  |  | |  9 |\n\nlow income  \nIndia (n=7)  \n141.1  \nother low income (n=15)  \nlowermiddle income (n=15)  \nupper middleincome (n=4)  \nlow income  \nIndia (n=7)  \nother low income (n=17)  \nlowermiddle income (n=13)  \nupper middleincome (n=3)  \nmax min  \n􀂃 mean  \nOriginator brands Lowest priced generics  \nDifferences between originator brands & lowest priced generics,  \nmatched pairs, private sector","cbCaimR7mO1m3c6U","https://ap.wps.com/l/cbCaimR7mO1m3c6U","pdf",1182937,18,"English","# Medicine prices and availability project overview\n## Objectives and key activities\n## Facility-based survey measures\n## WHO/HAI standard methodology and resources\n## Results and indicators from surveys\n### Availability by income group\n### Availability for acute vs chronic conditions\n### Patient prices and procurement effects\n### Median patient prices by sector and adjustments","[{\"question\":\"What does the WHO/HAI project aim to improve regarding essential medicines?\",\"answer\":\"It aims to improve the availability and affordability of essential medicines through better measurement and policy support.\"},{\"question\":\"What methodology does the project develop for collecting data?\",\"answer\":\"It develops and applies a reliable methodology to collect and analyse medicine price and availability data across healthcare sectors and regions within a country.\"},{\"question\":\"Which measures are included in the facility-based surveys?\",\"answer\":\"Facility-based surveys measure medicine prices, medicine availability, affordability of treatments, and components in the supply chain.\"}]","Medicine Prices and Availability - WHO/HAI Project | PDF",45]